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SEROANALYSIS OF FELIS CATUS GAMMAHERPESVIRUS 1 INFECTION IN DOMESTIC CATS 
 
We recently described a novel herpesvirus of domestic cats, Felis catus gammaherpesvirus 1 
(FcaGHV1).  FcaGHV1 is a member of the gammaherpesvirus subfamily, which also includes the 
human cancer-associated herpesviruses, Epstein-Barr virus (EBV) and Kaposi’s sarcoma-
associated herpesvirus (KSHV). To determine FcaGHV1 antigens that elicit a detectable 
humoral-immune response in naturally-infected domestic cats, I chose to evaluate seven 
FcaGHV1 proteins. These proteins are conserved across the subfamily and antigenic in other 
gammaherpesvirus infections. I amplified and cloned each of the seven FcaGHV1 genes into a 
mammalian expression vector and transfected intact clones into Crandell Rees feline kidney 
(CRFK) cells.  I developed an immunofluorescent antibody test using transfected cells exposed 
to sera from nine shelter cats diagnosed as FcaGHV1-positive by quantitative PCR (qPCR) of 
blood-cell DNA. This analysis indicated that tegument proteins ORF52 and ORF38 reacted most 
consistently with serum from cats with positive FcaGHV1-qPCR reactions. Based on these 
results, recombinant antigens were used to develop two optimized indirect ELISAs. Genes for 
ORF52 and ORF38 were cloned into a mammalian expression vector. Antigens were produced in 
a transient transfection system and purified using immunoprecipitation.  Indirect ELISA 
conditions were optimized using known positive and negative controls.  Using the two 
optimized ELISAs, I screened sera from 133 shelter cats that had been previously tested by 
FcaGHV1-qPCR. Seroprevalence of FcaGHV1 reactive antibodies was 32%, compared to the 
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previously published 16% prevalence evaluated by qPCR.  Nineteen of twenty qPCR positive 
cats were also seroreactive against one or both antigens on ELISA. Sera from 24 cats were 
seropositive based upon ELISA testing, but negative using qPCR analysis. Risk factors identified 
in previous publications were confirmed by ELISA, namely geographic location, male sex, adult 
age, and association of FcaGHV1 with several co-infections. Based on our knowledge of 
gammaherpesvirus latency, this ELISA provides evidence of viral exposure, while qPCR viral DNA 
detection likely represents reactivation from latency or primary infection. The addition of 
serologic analysis as a measurement of FcaGHV1 exposure will aid in determining association of 
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The herpesviruses have 3 subfamilies: alpha, beta, and gamma. Alphaherpesviruses 
have more notoriety, causing mild to moderate disease and with potential to cause severe 
disease in the face of immune suppression2,3. Many alphaherpesviruses also establish latency in 
sensory ganglia3. The beta and gammaherpes viruses are not as well characterized; however 
they can still be powerful agents of disease4,5. The gammaherpesviruses are known for being 
highly host specific and often target B or T lymphocytes3. Latent gammaherpesvirus is 
commonly found in lymphoid tissue3,4.  
Epstein-Barr virus (EBV) and Kaposi’s sarcoma associated herpes virus (KSHV) are 
examples of human gammaherpesviruses3,6,7. EBV causes mononucleosis upon initial infection 
and retreats into latency3,7. Reactivation is associated with immunosuppression such as HIV 
infection3,4. At this stage, EBV is associated with a range of lymphoproliferative disorders3,7,8. 
Not as much is known about KSHV pathogenesis.  KSHV causes mild disease, if at all, during 
primary infection9; instead it seems to require a cofactor to develop disease10. Immune 
suppression appears to play a role as cofactor; under these circumstances KSHV causes Kaposi 
sarcoma6,10,11, primary effusion lymphoma12, multicentric Castleman’s disease, and other non-
Hodgkin lymphomas13.  
Prior to the discovery of Felis catus gammaherpesvirus 1 (FcaGHV1), there were no 
described gammaherpesviruses of the domestic cat. There is an available real time PCR (qPCR) 
assay that quantitates FcaGHV1 viral DNA in whole blood samples1. This assay aided 
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identification of risk factors for FcaGHV1 infection. However, many questions remained 
unanswered about virus transmission, and disease association that could be addressed by 
development of serodiagnostics to detect viral exposure and test associations with disease 
states.  
 Studies of antigens for EBV and KSHV have revealed a variety of antigens with a varied 
response14-17. In one KSHV study to evaluate seroprevalence of patients with KS, western blot 
was conducted for a variety of KSHV antigens as a prelude to ELISA development. This study led 
to successful creation of a sensitive KS ELISA, and discovered a varied serologic response to the 
ELISAs they created for 5 antigens14. 
Thus for my thesis, I sought to develop a high-throughput, sensitive, and specific 
serologic assay that was capable of detecting antibodies to FcaGHV1. During herpes viral 
latency, intact viral genomes are maintained in certain host cells, even though the virus is not 
actively replicating18. For several gammaherpesviruses including EBV, qPCR of peripheral blood 
is used to quantitate viral load and document viral activation. EBV negative qPCR assay 
indicates latency or no infection19. My hypothesis is that an FcaGHV1 antibody detection assay 
will show a higher disease prevalence in the cat population than the qPCR assay, because it will 
be able to detect cats infected with latent FcaGHV1 as well as cats with actively replicating 
virus.  Secondarily, qPCR positive cats should also be seropositive, indicating that animals are 
mounting an active humoral immune response to FcaGHV1 infection.  
My specific aims and hypotheses were as follows:  
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Aim 1:  To identify FcaGHV1 antigens that elicit a humoral antibody response in naturally 
infected domestic cats  
Hypothesis:  FcaGHV1 antigens that elicit a detectable immune response are analogues of 
immunodominant antigens identified in gammaherpesvirus infections of other species. 
Approach: Select genes from FcaGHV1 partially annotated genome based on homology to 
KSHV, EBV, and OvHV-2. Clone selected genes into a mammalian expression vector containing a 
human influenza hemagglutinin (HA) tag.  Verify sequence of the clone, and transfect Crandell 
Rees feline kidney cell line (CRFK). Develop an immunofluorescence antigen screening assay 
(IFA). Positive controls include anti-HA antibody to confirm transfection, and cells transfected 
with the FIV capsid antigen tested with serum from an FIV-positive cat.  Negative controls 
include serum from naïve, specific pathogen-free (SPF) cats, vector-only control transfections, 
and untransfected cell controls. Then, I will test serum from 9 cats that were FcaGHV1 positive 
by qPCR to validate the IFA and identify FcaGHV1 antigens that react to cat serum in a sensitive 
and specific way. IFA antibody response will be additionally validated by western blot using 
transfected cell lysates as immobilized antigen. 
 
Aim 2: To design a sensitive, specific, reproducible serologic assay using one or more FcaGHV1 
antigens. 
Hypothesis: Immunodominant proteins of FcaGHV1 can be used to develop a serologic assay for 
testing feline seroprevalence to FcaGHV1.   
Approach: Express selected proteins in 293T cells using the similar methods employed during 
IFA development. Purify FcaGHV1 antigens using magnetic anti-HA immunoprecipitation. 
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Develop an indirect immunoassay to evaluate antibody reactivity in domestic cat serum banks 
to one or more FcaGHV1 antigens. Establish controls and optimize assays.  
 
Aim 3: To compare FcaGHV1 prevalence in selected cat cohorts using qPCR and serologic assay. 
Hypothesis: FcaGHV1 serologic assay will reveal a higher FcaGHV1 prevalence than detected 
using qPCR, and qPCR positivity will be highly correlated with seropositivity. 
Approach: Test serum samples from 133 cats from three geographic areas of the US with 
known FcaGHV1 qPCR status. Compare the results of the qPCR assay and serologic assay using 
appropriate statistical comparisons.  Analyze and compare results of the two assays along with 
predictor variables: sex, age, geographic location, and co-infection status using appropriate 












Felis catus gammaherpesvirus 1 (FcaGHV1) was recently discovered in the domestic cat 
and has a worldwide distribution1. While only preliminary information has been established 
relating FcaGHV1 infection to demographic factors, other species of gammaherpesvirus (GHV) 
subfamily of Herpesviridae have been studied in-depth. Most GHVs are highly specific to their 
host species20,21 making it especially challenging to learn more about human GHVs. Epstein-Barr 
virus (EBV) and Kaposi’s sarcoma-associated herpes virus (KSHV) are human GHVs that pose 
important health risks. Diseases of EBV, KSHV and other GHVs appear to be more severe in 
immunocompromised individuals4,10,18. For example, KSHV causes primary effusion lymphoma 
(PEL) in immune suppressed patients22,23. PEL is a serious condition with median survival of 6 
months even in patients undergoing currently accepted therapies24. Further research on 
FcaGHV1 will not only benefit cat health, but could also provide a model of naturally occurring 
infection for better understanding of EBV and KSHV infection in humans.  
All known herpes viruses establish a latent, life-long infection18. GHVs often cause 
lymphoproliferative disease as well as non-lymphoid cancers with re-activation from latency8,18. 
For example, EBV often manifests as infectious mononucleosis upon initial infection, then 
persists in memory B-cells as a latent infection for the life of the individual18,7. When the 
immune system is suppressed by old age, transplant surgery, or other infections, EBV can re-
activate. EBV is strongly associated with Hodgkin lymphoma, non-Hodgkin lymphoma, Burkitt 
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lymphoma, B-cell lymphoma of immunosuppression, and nasopharyngeal carcinoma7. In 
contrast to EBV, initial infection of KSHV often does not cause disease9. However, it is 
considered a necessary factor in the direct cause of several diseases: Kaposi’s sarcoma, PEL, and 
multicentric Castleman’s disease in immune suppressed patients9,22,23.  
Herpes virion structure is similar across the family. Virion diameter ranges from 120-
300nm. It consists of a DNA core, followed by a capsid layer, tegument layer and envelope. The 
core of the herpesvirus is usually torus-shaped.3 The capsid has 162 capsomers including both 
pentameric and hexameric capsomers. The tegument is an ordered structure between the 
capsid and envelope. Layer thickness may vary across the virion and from one particle to 
another. Herpes viral envelopes are trilaminar with numerous short glycoprotein protrusions.3 
The relationship of FIV and FcaGHV1 may provide a parallel opportunity to study HIV 
and human GHVs25. FIV is already an established model for HIV because of the disease 
similarities26,27,28. Patients co-infected with AIDS and either KSHV or EBV are at a greater risk of 
developing disorders related to these gammaherpesviruses4,10,29. Treatment for GHV-related 
lymphoproliferative disease provides many challenges for the AIDS patient10. There is a striking 
similarity between viral loads in EBV/HIV co-infection patients and cats with FcaGHV1/FIV co-
infection. Cats that are co-infected with FIV and FcaGHV1 have higher viral loads of FcaGHV125. 
This pattern closely resembles HIV and EBV co-infection21. Human viruses of the 
gammaherpesvirus subfamily are difficult to study because of the wide range of proteins that 
are expressed during lytic and latent phases of viral infection11,30. Small animal model 
limitations have compounded this problem 11. There is a clear deficit of EBV animal models and 
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a call for more work in this area 31. KSHV in vivo models are arguably even less robust10. Much 
of the current knowledge base on EBV from studying murine herpes virus 68 (MHV-68)32. One 
of the major obstacles to progress in the field using this model is that the virus biology for 
MHV-68 is in some ways more similar to the alphaherpesviruses 32. The humanized mouse 
model is promising, but it remains to be seen whether this model can truly address virus 
pathology given the significant physiologic differences between mice and humans33,34. Using 
FcaGHV1 in cats to model this relationship could provide a unique, cost-effective opportunity to 
explore the relationship between HIV and EBV in a host that is genetically more closely related 
to humans, affords a greater opportunity to assess temporal disease, and is easily maintained. 
However, additional diagnostics are needed to explore this potential model of disease. 
Our lab developed a real time PCR (qPCR) assay that detected FcaGHV1 in 16% of US 
shelter cats1 and domestic cats infected with FcaGHV1 across three continents25. Results of our 
qPCR assay revealed several risk factors for FcaGHV1, including being male, adult, and having 
evidence of co-pathogens. This suggests aggressive male encounters as a potential factor for 
FcaGHV1 transmission. Older age and a veterinary evaluation of “poor health” were also 
associated with FcaGHV125,1. The relationship to FcaGHV1 infection and co-infection status 
potentially implicates reactivation of FcaGHV1 due to immune suppression.  
We hypothesized that the measure of prevalence from our qPCR assay underestimates 
exposure to FcaGHV1 by not accounting for animals with latent infection. FcaGHV1 qPCR 
measures peripheral FcaGHV1 DNA viral load which is a measure of active viral replication and, 
in gammaherpesviruses, can be a good marker of primary infection or re-activation. An ELISA 
can assess humoral antibody status, which can indicate exposure but not necessarily an active 
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infection. Due to similarities within the GHV subfamily, it is likely that FcaGHV1 viral-load 
variation mimics patterns of EBV variation. If so, asymptomatic cats infected with FcaGHV1 
would be seropositive but would have low or undetectable viral loads19. The serologic assays 
we developed in this project helped to resolve this question of exposure rate. 
Here, we developed an indirect ELISA to answer the question of feline exposure to 
FcaGHV1. We evaluated serum from 133 shelter cats that had previously been tested for 
FcaGHV1 by blood-viral load qPCR1,25. We compared the data we have on age, sex, and co-
infection status to evaluate differences between qPCR results and seroprevalence. Results 
identified seroprevalence as a potential measure of FcaGHV1 exposure and qPCR as a measure 
for active FcaGHV1 infection. This information provides a valuable contribution to the growing 
knowledge of FcaGHV1 and further information about its potential as a model of human GHVs. 
MATERIALS AND METHODS 
Gene selection for identification of immunodominant antigens: 
In a corollary study, our laboratory has obtained partial FcaGHV1 genome data to map 
FcaGHV1 genes to other GHVs genes (unpublished data). We selected 7 conserved genes from 
this dataset to evaluate for potential to elicit humoral immunity in naturally infected cats.  
These included ORF38, ORF42, ORF59, ORF26, ORF52, ORF17.5, and ORF65 which code for 
proteins analogous to antigenic proteins of KSHV, EBV, and OvHV-2. All 7 proteins are virion-
associated (Table 1). The initial list of genes also included ORF8 (glycoprotein B). The 
glycoproteins are classic antibody targets because of their location on the outside of the virion3. 
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Attempts at cloning ORF8 provided quite a few technical challenges and initially were all 
unsuccessful. We postponed work with ORF8 in the interest of the time frame of this study. 
Table 1. FcaGHV1 protein analogs are antigenic in other gammaherpesviruses. Malignant catarrhal 
fever-causing viruses (MCFVs) include Ovine herpes virus 2 and Alcelaphine herpes virus 1. EBV has 
distinct gene nomenclature listed in parentheses. 
Gene Type of protein Analog to protein from Possible function 
ORF17.5 Scaffold protein MCFVs35 Involved in capsid assembly36 
ORF38 Tegument KSHV17 Support virion maturation in the cytoplasm37 
ORF52 Tegument EBV (BLRF2) 38,39 Assist virion egress and secondary envelopment38 
ORF65 Capsid EBV (BFRF3) 
39, KSHV14,40, 
MCFVs35 Small capsid protein
41, late gene42 
ORF26 Capsid EBV (BDLF1)43 Capsid protein41, late gene42 
ORF59 Phosphoprotein KSHV14 
Binds DNA polymerase and dsDNA to 
promote DNA synthesis by acting as a 
sliding clamp44 
ORF42 Tegument EBV (BBRF2) 45 May contribute to the regulation of mitochondrial function46 
 
Plasmids 
Specific primers that incorporated restriction sites were designed for each gene of 
interest based on our FcaGHV1 genome map (Table 2). All genes were PCR-amplified using a 
High Fidelity Platinum Taq PCR protocol from template DNA extracted from a cat infected with 
FcaGHV1 of confirmed sequence. PCR products were run on a 1% agarose gel to confirm 
expected nucleotide length. Bands were excised and DNA extracted using the manufacturer’s 
standard protocol with a Qiagen gel extraction kit. Concentration of amplicon DNA was 
evaluated with a NanoDrop spectrophotometer.   
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Reactions for restriction digest of amplicons were designed exactly as outlined by the 
New England Biolab NEBcloner online protocol development tool for digests in 50µL reactions. 
BamHI HF and EcoRI HF were used to cut all gene amplicons and the pKH3 vector except 
ORF17.5, BclI was used in place of BamHI for ORF17.5 restriction digest and the coordinating 
vector digest. After digest, the reactions were run on a 1% agarose gel and bands of the 
expected nucleotide length were extracted and purified with the Qiagen gel extraction kit. The 
NanoDrop spectrophotometer was again used to evaluate concentration.  
These restriction enzyme digested amplicons were then ligated into the pKH3 vector 
using corresponding cloning sites and New England Biolab T4 DNA ligase and coordinating 
manufacturer protocol for cohesive ends. Reactions were each 20µL and ligation performed 
using a molar ratio of 1:3, vector to insert. The pKH3 vector which contains an HA tag, was a gift 
from Joel Rovnak and Sandra Quackenbush.  
Plasmid constructs were transformed in OneShot Chemically Competent cells using 
suggested protocols by the manufacturer. Ten colonies from each transformation were 
screened by PCR targeting each insert and products were run on a gel to ensure that the insert 
was the correct nucleotide length. Three colonies of appropriate insert size were selected to 
propagate overnight in Lysogeny broth (LB) + ampicillin. Inserts from selected colonies were 
sequenced to confirm identity at Colorado State University Proteomics and Metabolics Facility. 
One clone with perfect sequence was selected for each gene insert. A glycerol stock was 
created for the selected colony for long term storage. Plasmid was purified from this selected 
colony using the Qiagen plasmid mini and midi spin prep protocols.  
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The FIV Gag capsid protein (p27), used as a control for the immunofluorescence assay, 
was acquired from a previous study47. It had been cloned into a pGEX2T vector with the same 
reading frame as pKH3. Restriction digest was performed with the FIVCA-pGEX2T using BamHI 
HF and EcoRI HF with the same protocols as described earlier for the other constructs. The 
product was run on a 1% agarose gel to select the correct insert size and purified using the 
Qiagen gel purification kit. All the following steps described earlier were performed identically 
to the other constructs, that is: ligation of FIVCA into pKH3, transformation, storage, and 
plasmid purification.  
Table 2. Primers used for assay development. Open reading frame (ORF) primers were used to amplify 








CRFK cell cultures were maintained with CRFK media made from low glucose DMEM + 
glutamax (Life Technologies brand), with added 10% fetal bovine serum (FBS), 1% sodium 
Gene Primers 
ORF17.5 5’- AGACGCTGATCAATGGCCACTAATGCCAG -3’ 5’- CCTGAATTCCTATTAGTTTTTTAGAAGTTCTTCACAAAATA -3’ 
ORF38 5’- CGCGGATCCATGGGTATCATCTGCTCTATTT -3’ 5’- CCGGAATTCCTATCAGATACTAAATACAACTTTCTTTTTTATC -3’ 
ORF52 5’- CGCGGATCCATGGCTTCTAAAAAAGGAACACC -3’ 5’- CCTGAATTCCTATTAGGTTGGTTGTTTGGATCTAC -3’ 
ORF65 5’- CGCGGATCCATGAGTAGGGAACAGTTAAGAG -3’ 5’- CCGGAATTCCTATTATTTTTTTTTGCTTCCACTAGTTG -3’ 
ORF26 5’- CGCGGATCCATGCAAGTTGATAAAAAAATCATAGTC -3’ 5’- CCGGAATTCCTACTAGATGGACAACCAGCCT -3’ 
ORF59 5’- CGCGGATCCATGGAAGCTAAAATTACTACTCACTA -3’ 5’- CCGGAATTCCTATTATGTTGTAATCTTGGAATGTTTTG -3’ 
ORF42 5’- CGCGGATCCATGGACTCTGTAATCCGAACC -3’ 5’- CCTGAATTCCTATTATGAAAAGATTTGTACTCTAGGCTT -3’ 
pKH3 5’- CAACTGCACCTCGGTTCTA -3’ 5’- CCATTATAAGCTGCAATAAACAAGT -3’ 
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bicarbonate, 1% Penicillin/Streptomycin (Pen-strep) and 1% non-essential amino acids. For 
additional culture maintenance, they were passaged when confluent (bi-weekly) using trypsin.  
For the immunofluorescence assay (IFA), CRFKs were grown on glass slides with twelve 
0.4mm wells with the CRFK media mentioned earlier except for no added antibiotic. CRFKs 
were plated at 5,000 cells per well and incubated for 2 days to allow adherence to the slide. 
Slides were housed in petri dishes with sterile water to maintain humidity. Transfections with 
plasmid constructs were performed using Lipofectamine 2000 protocols in 0.4mm well, using 
0.15µL Lipofectamine and 60ng plasmid per well. Cells were incubated for 21 hours. This time 
length was selected as optimal for protein expression of FIVCA. This time was kept the same for 
all transfections and no further experiments were done to optimize time length to specific 
genes used in the transfection.  
After incubation, slides were gently washed with PBS to remove excess media. Cells 
were then fixed using 2% paraformaldehyde and then 50:50 ethanol/methanol followed by air-
drying. The experimental serum used was obtained from nine cats sampled at shelters in CO, 
CA, or FL previously shown to have high peripheral FcaGHV1 DNA viral loads1. Each set of cells 
transfected to produce the selected proteins were tested with serum from all nine FcaGHV1-
positive cats. Transfected cells were also tested with negative control serum from three specific 
pathogen-free (SPF) cats from the CSU SPF retrovirus research cat colony.  This colony has been 
extensively screened and shown to be FcaGHV1 negative. An FIV-antigen capsid protein was 
used to transfect CRFK cells as described above; exposure to banked FIV-positive serum was 
used to demonstrate successful transfection and appropriate IFA parameters. Additionally, to 
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test for protein expression by evaluating the presence of the N-terminal HA tag included in each 
construct, cells were incubated with Covance rabbit-anti-HA at a 1:500 dilution. Slides were 
incubated for 1hr at 37C with primary antibodies followed by three more washes with PBS in 
preparation for secondary antibody exposure.   
The secondary antibody used for the rabbit-anti-HA was Covance anti-rabbit-IgG 
conjugated to fluorescein isothiocyanate (FITC) diluted to 1:500. Secondary antibody to detect 
feline serum antibodies (Covance anti-cat-IgG FITC) was used at 1:50 and incubated 1hr at 37C 
followed by 3 PBS washes and a 2 min 4', 6-diamidino-2-phenylindole (DAPI) nuclear stain. All 
sera described earlier and commercial antibody was diluted in 2% bovine serum albumin (BSA) 
in PBS. All sera were diluted at 1:20 in BSA/PBS and commercial antibodies at the listed ratios in 
BSA/PBS. Slide covers were sealed with ProLong Gold Antifade prior to light microscopic 
viewing (with an Olympus BX60) for immunofluorescence.  
Positive results were recorded if there was at least one cell per well that had a stronger 
immunofluorescence than the strongest background visible on the (negative) wells exposed to 
SPF naïve serum. This immunofluorescence was also compared to surrounding negative cells 
within the well when evaluating positive versus negative. Images were recorded with the 
microscope-connected Olympus DD71 digital capture system. Uniform adjustments were made 
with Photoshop to improve overall brightness of images for presentation.  
Western blot for confirmation of immunodominant antigens 
Immunoblot analysis was performed to confirm IFA observations on two candidate 
antigens demonstrating the most consistent immunofluorescence against qPCR positive 
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FcaGHV1 cat sera. ORF38 and ORF52 were semi-purified from cell lysates (transfection 
conditions using Lipofectamine 2000 described earlier scaled-up for 6-well tissue culture plates) 
using the Pierce magnetic anti-HA IP/ co-IP kit and following manufacturer instructions. After 
immunoprecipitation, protein concentration was determined using the Pierce BCA kit. NuPage 
1.5mm, 4-12% Bis-Tris 10 well gels were used in the NuPage gel box with associated 20x 
NuPage MES Running Buffer (1M Tris-Base, 1M MES, 2.0%SDS, 2mM EDTA) diluted to 1x 
working buffer. The power supply was set at 160V for 40min. For each protein being evaluated, 
1µg of protein per well was used, with enough wells to evaluate the different samples. The Bio-
Rad Precision Plus Blue and Magic Mark standards were run for each gel.  
Gels were transferred to PVDF membrane using 1x working stock of the 20x NuPage 
transfer buffer with added 10% methanol. The gel and PVDF membrane were sandwiched 
between 9 layers of blotting paper. Transfers were done in a Trans-Blot Turbo Transfer System 
at 15V for 30min. The PVDF membrane was blocked for 1 hour with 5% non-fat dry milk protein 
in PBS, and then cut into strips for exposure to serum from 9 qPCR positive cats and 3 SPF naïve 
cats at 1:20 dilution in PBS for 1 hour. The strips were then washed in PBS plus 2% tween 
(PBST). The strips were incubated with goat anti-cat phosphatase labeled IgG for 1 hour at 
1:2000 in PBS. After an additional wash, strips were incubated with BCIP-NBT phosphatase 
substrate to visualize bands.  
To ensure the correct protein was on the membrane, one strip with each protein was 
incubated with Covance HA.11 mouse anti-HA antibody at 1:5000 and secondary goat anti-
mouse horse radish peroxidase (HRP) at 1:10000. Dilutions were in PBS and washes were 
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performed as described earlier with serum incubated strips. Equal amounts of peroxide solution 
and luminol (Millipore Immobilon Western HRP substrates) were applied to the strip and then 
visualized using chemiluminescent detection imaging (ImageQuant LAS 4000).  
 Protein expression for ELISAs 
ORF 38 and ORF52 were chosen for larger-scale production in 293T cells. 293T cells were 
maintained in 293T media (high glucose DMEM with added 2%Glutamax, 10% FBS, and 1% 
Pen/Strep). Cells were maintained by passaging when confluent on a biweekly basis.  
Eight million 293T cells were plated onto 100mm tissue culture plates in antibiotic free 
media and incubated overnight at 37C. Plasmid constructs that were developed for the IFA 
were transfected the following day with 45µL Lipofectamine 2000 and 18µg plasmid per plate 
for ORF52 and 60µL Lipofectamine 2000 and 15µg plasmid for ORF38. Optimem was used in the 
quantities recommended by Lipofectamine 2000 manufacturer protocols. Transfection length 
was found to be optimal at 20 hours. Cells were harvested and purified using the Pierce anti-HA 
magnetic bead kit and protein concentration determined by BCA assay, as described earlier, 
and stored at 4C. 
ELISAs 
ELISAs were performed in 96-well plates. Each protein was diluted in a 50mM carbonate 
buffer, 40ng ORF52 in 100µL buffer per well and 100ng ORF38 in 100µL buffer per well. Plates 
were incubated overnight at 4C. Contents were discarded and 300µL of 2% BSA in imidazole-
buffered saline (IBS) was used to block plates for 2 hours at room temperature. Contents of 
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block were discarded and wells were incubated at room temperature for 2-hours with 100µL 
serum per well, diluted 1:100 in ELISA diluent made with IBS. Plates were washed 5 times in a 
plate washer with IBS + 0.2% Tween (IBST).  
The secondary incubation was 1-hour at room temperature with 5% mouse sera, ELISA 
diluent and 1:5000 Cappel goat anti-cat IgG peroxidase conjugate. Wells were again washed in 
a plate washer 5 times with IBST. TMB-peroxidase detection solution was added to each well 
(100µL) and incubated for 10 min at room temperature. The reaction was stopped using 50µL 
per well of 2.5N H2SO4. Absorbances were read at 450nm. Serum from each cat and controls 
were run in triplicate. Controls run on every plate included serum from 3 different SPF naïve 
cats, no-antigen control wells, and diluent-only wells. 
Optimization was performed to identify the most appropriate dilutions of feline serum, 
secondary antibody, and concentration of coated antigen. Feline serum from an FcaGHV1 qPCR-
positive animal was used for the optimizations. A range of dilutions were initially attempted 
above and below the ones ultimately selected to identify the largest signal-to-background ratio. 
Only in the case of the ORF38, a coating concentration was selected that was suboptimal. This 
compromise was made because of the low protein yield from ORF38 transfections. All other 
dilutions were selected to have the highest signal-to-background ratio. 
Prior to initiation of sample testing each ELISA was tested with serum from 10 SPF naïve 
cats to ensure that there was no non-specific reaction occurring. Positive threshold was 
evaluated on a plate by plate basis: the mean absorbance of the replicates of the 3 SPF naïve 
cats was calculated with the addition of 3 standard deviations. Additionally, if this calculation 
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yielded a number <0.2, then 0.2 was considered the threshold for positive for that 96-well 
plate.  
Collection of samples  
Domestic cat blood samples were obtained from archived samples of ostensibly healthy 
animals. These samples were taken from cats upon admission to shelters Florida, California, and 
Colorado as previously described1. FcaGHV1 qPCR assay prevalence was performed on DNA 
extracted from blood cells as previously described1. Demographic data were recorded for each 
cat, also described previously1,25,48. Each cat was also previously evaluated for Calicivirus, Feline 
herpesvirus-1 (FHV1), Mycoplasma spp., Bartonella spp. and FIV. Calicivirus and FHV1 were 
evaluated by oral swab PCR, Bartonella spp. was tested both by IgG and PCR. Mycoplasma spp. 
was evaluated using PCR and FIV was by presence of antibody1,25,48. 
Statistical analysis 
Logistic regression was used to make statistical analysis of geographic data and FcaGHV1 
qPCR or ELISA result. Shelter and state were each modeled as categorical independent-variables 
along with sex and age as binary co-variables. In each model, FcaGHV1 ELISA result or qPCR 
result was the dependent (response) variable. Binary logistic regression was used to model each 
co-infection. FcaGHV1 ELISA or qPCR result was the binary dependent-variable and the co-
infection, sex, and age as independent binary co-variables. For sex and age, male was recorded 
as 1 and female as 0, similarly adult as 1 and young as 0. Odds ratios were calculated within the 
respective logistic models. Linear regression was used to evaluate correlation of absorbance 
and qPCR viral load. Logistic and linear regression modeling were performed in SAS.  
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Sensitivity and specificity was calculated using modeling techniques described by Liu et 
al49. This Bayesian model requires a gold standard test used to evaluate only the positive 
responses from two dependent screening tests along with positive and negative results from 
those assays. This was adapted to our study by considering the two ELISAs (ORF38 and ORF52) 
to be the dependent assays. The qPCR assay was considered a gold standard only for the sake 
of specificity (100%).  As with the model designed by Liu et al., two sensitivities were calculated 
for the ELISAs based on the association to qPCR specificity, only cats testing positive on qPCR 
were considered in this evaluation. This information was then used as informative priors for a 
second model to calculate specificity and sensitivity for each ELISA assay as well as prevalence. 
We used the open access WinBugs program written by Liu et al. to make these calculations49. 
Linear regression models were also created in SAS to evaluate the relationship between 
mean triplicate absorbances of qPCR-positive cats and their measured FcaGHV1 viral load. 
Separate analyses were done for ORF38 ELISA results and ORF52 ELISA. Viral load was modeled 
as the dependent variable (y). One cat with a viral load greater than 4 standard deviations 
outside the mean was removed from these analyses. T-tests were used to evaluate the 
relationship of the variables.  
A calculation of the rate of animals infected per year was performed similar to an 
incidence calculation. The following equation was used: 100 ×  (#qPCR positive cats / time span 
of captures in years/n).  
RESULTS  
Expression plasmid development and controls 
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Seven FcaGHV1 genes were selected from the FcaGHV1 genome (unpublished data) 
based on genome alignment to determine homologous genes that code for antigens of KSHV, 
EBV and malignant catarrhal fever causing viruses (MCFVs) (Table 1). Successful cloning of 
predicted targeted amplicons was verified by sequencing each construct. The pKH3 vector used 
for all plasmid constructs contains an HA tag that was expressed at the N-terminus of the 
protein of interest. The HA tag was used as a control measure to evaluate protein expression in 
CRFK cells with both IFA and western blot (Figs. 1, 2). As a positive control, we transfected CRFK 
cells with the antigenic, FIV-capsid protein (FIVCA) and exposed antigen to FIV-positive serum in 
both the IFA (Fig.1) and western blot (data not shown). FIVCA was inserted in the same pKH3 
vector and treated under the same conditions as other proteins. Quantity of DNA, quantity of 
transfection reagent, and incubation time for transfections used to produce all proteins in both 
IFA and western blot were optimized to yield the highest quantity of FIVCA protein.  
IFA  
To determine which proteins of FcaGHV1 elicited IgG antibody during a natural 
infection, we developed an immunofluorescence assay to screen and evaluate seven FcaGHV1 
proteins. Cells were fixed with paraformaldehyde and methanol/acetone. This exposed the 
transfected intracellular proteins to subsequently added antibodies. All CRFKs were also stained 
with DAPI. We were able to visualize immunofluorescent cells for all protein transfections after 
incubation with FITC-tagged anti-HA antibodies (Figs. 1, S1). All cells exposed to cat sera were 
subsequently incubated with an anti-cat-IgG FITC to visualize immunofluorescence. We 
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confirmed assay controls: FIVCA transfections incubated with FIV-positive serum antibodies and 
negative control SPF cat serum (Fig 1).  
We screened each of the seven FcaGHV1 antigens following transfection with serum 
from nine FcaGHV1-positive cats with high peripheral-DNA viral loads (Tables 3, S1, Figs. 1, S1). 
We assumed these animals would have detectable antibodies against FcaGHV1 antigens. 
ORF38, ORF65, ORF17.5, and ORF52 all had measurable serum antibody reactivity against one 
or more of the FcaGHV1-positive cat sera (Tables 3, S1, Fig. 1). ORF38 and ORF52 antigens 
reacted against more individual FcaGHV1 positive cat samples (Table 3, S1). No 
immunofluorescent antibody response was detected against ORF26, ORF59, or ORF42 (Table 
S1, Fig. S1). ORF59, analogue to a phosphoprotein that assists DNA polymerase44, was the only 
protein that localized only to the nucleus. All other proteins had visible fluorescence in the 
cytoplasm after anti-HA staining (Figs. 1, S1). 
Western blot analysis 
Western blots were performed with crude lysate for all proteins screened on IFA: 
ORF42, ORF26, ORF52, ORF65, ORF17.5, ORF38, and ORF59. However, background was too high 
to make conclusions except for FIVCA reactivity with FIV+ serum (data not shown). Figure S2 
shows a comparison of ORF38 crude lysate and semi-purified western blots (remaining crude 
lysate western blots are not shown).We then confirmed IFA results for ORF52, ORF38, and 
ORF65 via western blot by immobilizing semi-purified viral antigens versus sera from the same 
9 FcaGHV1 positive individuals (Fig. 2, Table 3, S1). Serum from 3 SPF cats was run against all 
proteins and was consistently negative (Fig. 2).  
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Indirect ELISA optimization 
Given preliminary seroreactivity against ORF38 and ORF 52, we proceeded to develop 
two indirect ELISAs with these antigens. We scaled-up production of protein in 293T cells using 
similar techniques employed for CRFK transfection in IFA and western blot. ORF52 had a 
consistently higher protein yield after purification of approximately 0.5µg/million cells 
transfected. Despite transfection optimization experiments, maximal ORF38 yield was 0.2µg 
protein/million cells transfected.   
Both ORF38 ELISA and ORF52 ELISA were screened with 10 SPF naïve cats revealing all 
negative results. Additionally every 96-well plate included 3 SPF naïve cats to define threshold 
calculations. Triplicate average absorbance for SPF cats ranged from 0.06-0.18 units for ORF52 
and 0.07-0.12 units for ORF38. Since some SPF cat absorbances occasionally had sporadic 
higher or lower results, threshold minimum was established at 0.2 absorbance units for both 
ORF38 and ORF52 ELISAs to ensure specificity. However, if the average plus 3 standard 
deviations of the SPF cat absorbances on a particular plate was higher than 0.2, then this 
became the established threshold for the plate. All three triplicates had to be higher than the 
plate threshold to be considered positive. We tested serum from 9 cats evaluated on IFA and 
western blot (Table 3) during assay development. Once assays were optimized, we repeated 
ELISA on serum from these cats and additional animals representing shelter animals across the 
US, for a total of 133 cats. Average absorbances for animals defined as FcaGHV1 ELISA positive 
ranged from 0.21-1.5 units for ORF52 ELISA and 0.27-1.4 units for ORF38 ELISA. 
Comparison of seroprevalence and qPCR results 
21 
 
To compare viral loads and immune responses, we surveyed 133 cats previously tested 
for FcaGHV1 prevalence via qPCR assay of peripheral whole-blood FcaGHV1 DNA1,25. These cats 
represented animals presented to 8 different shelters in three different states over a period of 
2-3 years depending on the shelter. To determine how many cats have an active infection in a 
given year, an equation was developed in the same format used for calculating incidence. The 
qPCR results were used in this equation and predicted an annual infection rate of 5 to 8 cats per 
100. This estimate was used to further evaluate seroprevalence as a measure of exposure.  
The original cohort contained 135 cats; however we did not have serum samples 
archived for 2 cats, so they were removed from the sample set. This modified sample set 
included 15% (20/133) qPCR positive animals. Thirty two percent (43/133) overall 
seroprevalence was calculated after combining results of the two antigens for the ELISAs (Fig. 
3D). Of the 20 cats that tested positive on qPCR, 19 also tested positive on serologic assay; this 
represented 44% of FcaGHV1 seropositive animals. Thus there were 22 cats testing negative on 
qPCR and positive on the combined serologic assay (Fig. 3).  
Figure 3 displays the categorical data results of each assay in comparison to the qPCR 
results from our previous publication1. ELISA results generally supported each other; only 1 cat 
was positive only by qPCR (ELISA negative), 1 cat was positive only with the ORF38 ELISA 
(ORF52 and qPCR negative) and 11 cats were only positive by ORF52 ELISA (ORF38 and qPCR 
negative).  All other cats were confirmed by at least 2 assays. To further support specificity of 
ELISAs, there was a non-significant positive trend (p=0.0705) with qPCR measured viral load vs 
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ELISA absorbances for ORF52 (Fig 6). The same analysis of ORF38 absorbances did not reveal a 
similar trend however (p= 0.902) (Fig.7).  
Sensitivity and Specificity  
A two stage Bayesian method49 was used to evaluate sensitivity and specificity of the 
ORF38 ELISA and the ORF52 ELISA. Sensitivity of ORF52 ELISA was estimated as 74.3% (95% CI: 
61.0 to 92.6), while specificity was calculated as 96.4% (95% CI: 90.7 to 99.8). ORF38 ELISA had 
a sensitivity of 57.9% (95% CI: 50.3 to 73.8) and specificity of 97.9% (95% CI: 93.5 to 99.9). Using 
this same Bayesian model accounting for sensitivity and specificity of the ELISAs, 
seroprevalence of FcaGHV1 was estimated at 30.6% (95% CI: 21.6 to 41.1). 
FcaGHV1 predictors and risk factor analysis  
For the rest of the analysis, we combined the ELISA results so that if a cat was positive 
with one or more antigens it was considered ELISA positive for comparison of regional data, risk 
factors, and co-infection status. We compared assay results by qPCR and ELISA with 
demographic information including location of the shelter cat, sex and age (Fig. 5).  We noted a 
uniform increase from qPCR prevalence to ELISA prevalence by location, sex, and age categories 
reflective of the overall increase in prevalence with the ELISA assay (Figs. 4, 5). Evidence of 
exposure to FcaGHV1 increased when seroprevalence was compared to qPCR prevalence.  
Detectable exposures increased from 4% (2/52) to 15% (8/52) in Colorado, 13% (4/31) to 29% 
(9/31) in Florida, and 28% (14/50) to 52% (26/50) in California (Fig. 4). Infection as measured by 
qPCR was 0% (0/54) for females, while seroprevalence was 13% (7/54). Male cats increased 
from 29% (20/70) qPCR prevalence to 49% (34/70) seroprevalence. Young cat qPCR prevalence 
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and seroprevalence remained at 0% (0/30) in stark contrast to 21% (20/95) qPCR prevalence in 
adults with a 42% (40/95) seroprevalence (Fig. 5).  
 We used logistic regression to find associations with the ELISA results for risk factors 
previously evaluated by qPCR (Tables 4-5). The risk factors of adult vs young (p=0.011) and male 
vs female (p=0.0001) were corroborated as risk factors identified with qPCR testing1 (Table 4). 
Male cats were 7.11 (CI: 2.623, 19.29) times more likely than females to be FcaGHV1 
seropositive. The odds ratio for FcaGHV1 seropositivity in adult cats was 43.7 (CI: 2.379, 800.8). 
The odds for a male cat, compared to female, to be qPCR positive was 43.975 (2.581, 749.1) 
and adult vs young 9.867 (CI: 1.951, ∞) (Table 5). It should be noted that wide confidence 
intervals are a reflection of the statistical modeling limits. There were no young cats that were 
either seropositive or qPCR positive for FcaGHV1 and no female cats that were qPCR positive. 
The result of this is quasi-complete separation of the data set which was accounted for using 
Firth’s penalized likelihood. This allows calculation of odds ratios and p values but with wide 
confidence intervals. 
There was a significant difference in ELISA result between locations capture by state 
p=0.0176 (Table 4). Similar differences also exist in the qPCR data, p=0.052. The widest 
separation of odds was California vs Colorado for either FcaGHV1 qPCR or ELISA test. Cats from 
California were 4.650 (CI: 1.601, 13.50) times more likely to be ELISA positive and 4.916 (CI: 
1.286, 18.79 times more likely to be qPCR positive than cats from Colorado. There wasn’t a 
significant difference in odds between California and Florida when comparing either qPCR or 
ELISA FcaGHV1 results (Table 4). There was no significant difference between shelter within the 
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states with our qPCR analysis (p=0.402), we did demonstrate significant differences among 
shelters when comparing seroprevalence (p=0.0429). Odds ratios were calculated to compare 
shelters within states only (Table 4). There were no significant differences between shelters in 
Colorado or Florida (data not shown). However in California, cats captured by Ventura Animal 
Services were 8.613 (CI: 1.257 to 59.02) times more likely to be seropositive when compared to 
cats captured by San Diego Feral Cat Coalition (Table 4). Although the locations of capture are 
within 250 miles of each other, cats from Ventura Animal Services were in areas of high human 
population density while the cats from San Diego were captured in rural areas of the Peninsular 
mountain range. 
We further evaluated associations of FcaGHV1 serology with exposure to other 
pathogens. Samples from these animals have previously been tested for 6 other infections: FIV, 
Bartonella spp., Mycoplasma haemominutum (Mhm), Mycoplasma haemofelis (Mhf), 
Calicivirus, and Feline herpesvirus 1(FHV-1)48.  Odds ratios and p values are summarized in 
Table S2. Bartonella spp. IgG was similarly associated to both FcaGHV1 ELISA and qPCR 
positivity. There was a near significant association with positive Bartonella spp. IgG response 
and FcaGHV1 seropositive response (p=0.0516) and a significant association with FcaGHV1 
qPCR positive cats (p=0.0404). In contrast, Bartonella spp PCR response differed between the 
two FcaGHV1 test groups. There was a clear absence of significance with a Bartonella spp. PCR 
positive result and FcaGHV1 seropositivity (p=0.4921) while qPCR positivity and positive 
Bartonella spp. PCR had a near significant association (p=0.0547). There was a similar dynamic 
as with Bartonella spp. PCR to associations with FIV antibody response.  Positive result of 
FcaGHV1 ELISA showed no association with FIV antibody positive results (p=0.1242), while 
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FcaGHV1 qPCR and FIV association was nearly significant (p=0.057). Mycoplasma 
haemominutum (Mhm) and Mycoplasma haemofelis (Mhf) were also previously tested for by 
PCR. Mhm was significant for both FcaGHV1 qPCR positive (p=0.0338) and ELISA positive cats 
(p< 0.0001). Mhf was not significant for either FcaGHV1 assay result, but much closer to 
significance for FcaGHV1 ELISA (p=0.0995) than qPCR (p=0.2656). Calicivirus and FHV1 positive 
results were not associated with FcaGHV1 positive assay results. 
 
        
        
        
        




Figure 1. IFA detects 
FcaGHV1 antibodies in 
infected cats. The left-hand 
side of the figure indicates 
the recombinant protein 
antigen that was transfected 
into each set of cells. SPF cat 
serum was used as a 
negative control in all assays. 
Fluorescence in the second 
column indicates cells 
expressing the protein of 
interest with an HA tag. 
Serum from nine FcaGHV1-
qPCR positive cats was used 
to screen each transfection 
reaction to determine if 
antibodies were present in 
cat sera for each antigen 
tested. Immunofluorescence 
in the third column indicates 
cells that bound cat serum 
antibody. Here we show 
representative results of IFA 

































FcaGHV1 qPCR-positive cat using proteins ORF38, ORF52, ORF65, and ORF17.5. The FIV capsid 
(FIVCA) was used as a positive control for detection of viral antigen when exposed to sera from FIV+ 
cats. A vector-only negative control was also run with each transfection (Fig S1).  
FIVCA= FIV capsid protein, ORF38 = tegument protein of FcaGHV1, ORF52= tegument protein of 
FcaGHV1, ORF17.5= scaffold protein of FcaGHV1, ORF65= capsid protein of FcaGHV1, anti-HA= 














Figure 2. Western blot results confirm IFA. Immobilized protein indicated at top. Each strip was 
incubated with the serum or anti-HA as primary antibody (listed below). Tabulated results are listed in 
Table 3. SPF cats (S1-3), GHV+ cats (G1-G9) 
 
    ORF38  ORF52 
PCR+ 
cat#  IFA wb ELISA  IFA wb ELISA 
G1 (CA)   + + +   + - + 
G2 (CO)   - - -   + - + 
G3 (CA)   + + +   + - + 
G4 (CA)   + + +   - - + 
G5 (FL)   - - -   - - - 
G6 (FL)   + + +   - - + 
G7 (CA)   + + +   - - + 
G8 (FL)   + + +   - - + 
G9 (FL)   + + +   + + + 
Total pos.   7 7 7    4 1 8 
Table 3. ELISA assays increase detection of infection with FcaGHV1.  Nine cat samples positive for 
FcaGHV1 by qPCR were used for antigen identification screening. Table shows which cats displayed a 
serum antibody response to ORF52 and ORF38 proteins on each respective immunofluorescence 




































A ORF52 ELISA+ 
ORF52 
ELISA- 
ORF38 ELISA+ 28 2 
ORF38 ELISA- 13 90 
   
B ORF38 ELISA+ 
ORF38 
ELISA- 
qPCR+ 17 3 
qPCR- 13 100 
   
C ORF52 ELISA+ 
ORF52 
ELISA- 
qPCR+ 18 2 

















Comparison of assay 
results by location: 
Colorado, Florida, and 
California. 
Figure 3.  FcaGHV1 ELISA results coincide with qPCR and show additional positive results. A.-C. 
Categorical data comparison of cats tested for all 3 assays: ORF38 ELISA, ORF52 ELISA, and evidence 
of qPCR FcaGHV1 viral DNA load. D. Comparison of FcaGHV1 serology to qPCR1 for 133 shelter cats. 





Table 4. Geographic risk factors identified by FcaGHV1 qPCR status are supported by FcaGHV1 ELISA 
result. P values were calculated for differences by state or shelter using categorical logistic regression 
modeling with sex and age as co-independent variables and qPCR or ELISA result as the response 
variable (y). Odds ratios (OR) were calculated to compare shelters in California: Ventura Animal Shelter, 
San Diego Feral Cat Coalition, and Corona Animal Shelter. Odds ratios between Colorado and Florida 
shelters were not significant (not shown). 
 
  y= ELISA y= qPCR 
  P (Wald) OR 95% CI P (Wald) OR 95% CI 
State 0.0176 - - 0.0520 - - 
California vs Colorado - 4.650 (1.601 to 13.50) - 4.916 (1.286 to 18.79) 
California vs Florida - 1.567 (0.449 to 5.467) - 0.941 (0.217 to 4.078) 
Florida vs Colorado - 2.967 (0.788 to 11.17) - 5.223 (0.942 to 28.96) 
Shelter 0.0429 - - 0.402 - - 
Ventura vs San Diego - 8.613 (1.257 to 59.02) - 2.189 (0.320 to 14.99) 








Table 5. Sex and age are highly significant risk factors for both FcaGHV1 qPCR and ELISA response. 




 y= ELISA y= qPCR 
 OR 95% CI OR 95% CI 
Male 7.110 (2.623 to 19.29) 43.98 (2.581 to 749.1) 
Adult 43.70 (2.379 to 800.8) 9.867 (1.951 to ∞) 
A B 
Figure 5. FcaGHV1 ELISA enhances infection detection across sex, and age categories. A. Assay 
comparison by sex: male (M) and female (F). Unknown sex not shown: n=9. B. Assay comparison by 
age. Unknown age not shown: n=8. P value from Wald testing shows significance of binary logistic 













































ORF38 ELISA absorbance 
Figure 7. Viral load and 
ORF38 ELISA absorbance 
are not significantly 
correlated.  T-test of linear 
regression indicates there 
is no relationship between 
the variables p=0.9024. 
One extreme outlier with a 
viral load 4 standard 
deviations above the mean 
was removed from the 
data set. Est. = estimated 
slope (x) with 95% 
confidence interval. 
 
Figure 6. Viral load vs 
ELISA absorbance for 
ORF52 trends positively. A 
t-test of the linear 
regression model shows a 
trend towards a significant 
relationship between the 2 
variables, p=0.0705. One 
extreme outlier (viral load 
4 standard deviations 
above the mean) was 
removed from the data 
set. Est. = estimated slope 






 Table S1. Feline serum antibody responses to other prospective antigens tested by IFA were not 
routinely reactive. FcaGHV1 positive cats (G1-9, qPCR-tested) showed no antibody response to ORF59, 
ORF26, or ORF42. ORF65 and ORF17.5 had fewer cats with an antibody response then ORF38 and 
ORF52. A semi-purified western blot (wb) was also run for ORF65. 
 ORF59 ORF65 ORF17.5 ORF26 ORF42 
 IFA IFA wb IFA IFA IFA 
G1 (CA) - - + - - - 
G2 (CO) - - - - - - 
G3 (CA) - + + + - - 
G4 (CA) - - - - - - 
G5 (FL) - - - - - - 
G6 (FL) - - - - - - 
G7 (CA) - - - - - - 
G8 (FL) - - - - - - 
G9 (FL) - + - - - - 
total pos. 0 2 2 1 0 0 
 
Table S2. FcaGHV1 ELISA and qPCR associate with coinfections in differing patterns. Predictor variables 
and coinfection data for FcaGHV1 positive serology. P value from Wald testing shows significance of 
binary logistic regression modeling with FcaGHV1 ELISA result or qPCR result as the response variable 
(y). Separate models were created with each co-infection as independent variables (x) along with sex 
and age as co-independent variables. Odds (OR) with 95% confidence interval (CI) of a positive FcaGHV1 
ELISA or qPCR result were calculated for each independent variable. This table also shows the number of 
animals in each model (n) and the number of positive animals for each independent disease variable 
within that sample (pos. xn). Bart. = Bartonella spp. Mhm =Mycoplasma haemominutum, Mhf 
=Mycoplasma haemofelis, FHV1= Feline herpesvirus 1. Both FHV1 and Calicivirus were tested by oral 
swab PCR. FIV, Mhm, and Mhf were evaluated with PCR testing. 
 y= ELISA y= qPCR 
 OR 95% CI P (Wald) n pos. xn OR 95% CI P (Wald) n pos. xn 
Bart. IgG 2.720 0.993 to 7.468 0.0516 117 30 3.148 1.051 to 9.425 0.0404 119 30 
Bart. PCR 1.570 0.432 to 5.726 0.4921 117 17 3.988 0.973 to 16.35 0.0547 119 17 
FIV 3.070 0.734 to 12.869 0.1242 120 15 3.983 0.959 to 16.53 0.0570 121 15 
Mhm 11.30 3.736 to 33.90 <.0001 115 35 3.369 1.098 to 10.34 0.0338 117 36 
Mhf 4.900 0.740 to 32.396 0.0995 115 11 2.271 0.536 to 9.620 0.2656 117 11 
Calicivirus 1.070 0.279 to 4.121 0.9184 118 15 0.865 0.201 to 3.713 0.8453 120 15 









Figure S1. IFA detects no antibody response to remaining FcaGHV1 proteins. The top of the figure 
indicates the recombinant protein that was transfected into each set of cells. SPF cat serum was used as 
a negative control in all assays. Fluorescence in the first row indicates cells expressing the protein of 
interest with an HA tag. Serum from nine FcaGHV1-qPCR positive cats was used to screen each 
transfection reaction to determine if antibodies were present in cat sera for each protein tested. 
Immunofluorescence in the third row indicates cells no antibody response to incubation with FcaGHV1+ 
cat serum. A vector-only negative control (pKH3) was also run with each transfection (Fig S1).  
ORF26 = capsid protein of FcaGHV1, ORF59= phosphoprotein of FcaGHV1, ORF42= tegument protein, 








Figure S2. Crude lysate western blots are inconclusive. The left panel shows immobilized crude ORF38 
protein immobilized, the right panel shows immobilized semi-purified ORF38. Each strip was incubated 

































































As hypothesized, we detected a higher prevalence of FcaGHV1 in a population of 133 
shelter cats via ELISA (32%) compared to qPCR positive individuals (15%). Antibody response 
reflects exposure to the virus while qPCR assay more likely measures an active or reactivated 
viral infection. From this analysis we conclude that close to half (44%) of FcaGHV1 seropositive 
cats have a qPCR detectable FcaGHV1 viral load. Our measured FcaGHV1 seroprevalence is 
much lower than the seroprevalence of EBV in humans, which has a global seroprevalence of 
greater than 95% 50. The seroprevalence of FcaGHV1 in cats more closely resembles the 
seroprevalence of KSHV in humans. There is wide variation in KSHV seroprevalence rates partly 
because there is no gold standard assay9. Furthermore, reported KSHV exposures range 
dramatically by region. North America, Asia, and Europe are considered low seroprevalence 
areas and most studies have indicated exposure rates of <5%9. However, one study which 
tested routine pediatric patients in southern Texas by immunofluorescence assay, ELISA, and 
immunoblot found a seroprevalence of 26%51. Higher KSHV seroprevalence, approximately 
50%, is found in regions of Africa and also the Brazilian Amazon9.  
Studies to date have suggested FcaGHV1 has a closer phylogenetic relationship to KSHV 
than EBV1, and it has genes homologous to KSHV that are not conserved in other 
gammaherpesviruses, such as latency-associated nuclear antigen (LANA) (unpublished data). 
Assuming that the FcaGHV1 ELISA assays reported in these studies are sensitive enough to 
identify most of the cats exposed to FcaGHV1, seroprevalence is below 60%, similar to KSHV. 
KSHV’s lower seroprevalence and high regional variation might be due to factors involved with 
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virus shedding52. Twenty to thirty percent of healthy adults with latent EBV infection 
intermittently shed virus in oral secretions 50. High rates of KSHV shedding in healthy adults is 
individual specific and highly sporadic. Variation in KSHV shedding plays a role in regions with 
high rates of mother-to-child transmission through direct contact with saliva. There is evidence 
to show that this KSHV persistent shedding is related to host genetic factors52. FcaGHV1 may 
also have similar host genetic factors to KSHV that result in some infected cats being more likely 
to shed virus.  Since an increase in KSHV replication is associated with development of KS52, 
future studies should evaluate relationships between FcaGHV1 exposure and feline neoplastic 
disorders. 
The results of this ELISA data strongly corroborate age and sex as risk factors for 
FcaGHV1 that were identified previously1,25. Being male and adult appears to be strongly 
associated both with qPCR-positive FcaGHV1 infection (p=0.009, p=0.004) and ELISA-positive 
results (p=0.0001, p=0.011) (Fig. 5, Table 5). Interestingly, no young cats (n=30) were 
seropositive for FcaGHV1, and while some female cats in this population were seropositive 
(7/54), none were qPCR-positive. This suggests that mother-to-kitten, vertical transmission, or 
vector borne disease transmission are unlikely modes of spread of FcaGHV1 in the US feral cat 
populations. Aggressive contacts between males is a more probable mode of transmission given 
the strong association of infection with older male attributes.  An adult cat may have more 
aggressive encounters as well as a longer time to contract infection than a young animal. 
FcaGHV1 ELISA seroprevalence and qPCR data also demonstrated a potential correlation 
between exposure to FcaGHV1 and co-infection with other pathogens25. This might be related 
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to pathogenesis of FcaGHV1 and also to similar routes of transmission and risk factors between 
agents. Mycoplasma spp. and FIV are thought to be transmitted via antagonistic 
encounters53,54. Comparisons of FcaGHV1 ELISA and qPCR showed some associative trends with 
detection of FIV antibodies and FcaGHV1 qPCR-positive response (p=0.057). There was also a 
significant association with Mycoplasma haemofelis PCR-positive animals and both ELISA-
positive (p<0.0001) and qPCR-positive FcaGHV1 results (p=0.0338) (Table S2).  
Human gammaherpesviruses can be transmitted through direct contact with saliva. EBV 
is transmitted mostly through salivary secretions50. The most current information suggests 
saliva is the major route for KSHV infection as well50. Initially it was thought that KSHV was 
transmitted sexually55. More recent studies have shown that KSHV viral secretions are highest 
in oral mucosa56, with further evidence of high seroprevalence estimates from populations of 
children51,57  where vertical transmission probably plays a minor role58.  
With the assumption that reactivated FcaGHV1 infection would occur after the onset of 
an immune suppression event, I expected to see an association with multiple co-infections in 
cats FcaGHV1-positive in an assay that measures viral load (qPCR) and no association in cats 
positive in an assay thought to measure FcaGHV1 exposure (ELISA). There were some trends 
suggesting this with Bartonella spp. PCR positivity and FIV antibodies (Table S2), but it is difficult 
to make any concrete conclusions when looking at associations between multiple variables 
likely dependent on, not causal to, immune suppression. 
Geographic variation was a risk factor for both FcaGHV1 seropositivity and FcaGHV1 
qPCR positive result. Cats captured in California were 4.916 (95% CI: 1.286, 18.79) times more 
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likely to be qPCR positive and 4.65 (95% CI: 1.601, 13.50) times more likely to be ELISA positive 
than Colorado cats (Table 4). Moreover, a comparison of shelters revealed no significance in 
qPCR results, however, cats from Ventura Animal Shelter were 8.613 (95% CI: 1.257, 59.02) 
times more likely to be ELISA positive than cats captured by the San Diego Feral Cat Coalition. 
Both of these shelters were located in California (Table 4). A closer analysis of the geography 
reveals that the sample of cats in California likely came from much denser, city populations. 
Additionally, the majority of the cats captured by the San Diego group were in mountainous 
areas several hours from San Diego with low human populations, whereas the Ventura Animal 
Shelter captured cats in urban Ventura. This information suggests that feline population density 
may play a role in FcaGHV1 transmission. High density may also correspond with increased 
aggressive encounters further supporting this as a major mode of viral transmission. 
Sensitivity and specificity are difficult to measure without a gold standard test. In order 
to use Bayesian probability, at least 2 tests must be compared59. The two assay types in this 
study, qPCR and ELISA do not evaluate the same thing, active viral infection vs viral exposure. 
Therefore, sensitivity and specificity cannot be evaluated with this method. However, ORF38 
and ORF52 ELISA assays could be evaluated using a Bayesian logistic regression model. From 
these calculations, the ORF38 ELISA had a sensitivity of 57.9% (95% CI: 50.3 to 73.8) and 
specificity of 97.9% (95% CI: 93.5 to 99.9) while ORF52 ELISA had (95% CI: 90.7 to 99.8) 
specificity and 74.3% (95% CI: 61.0 to 92.6) sensitivity. The accuracy of these estimates is only 
as good as the probability distributions of the known parameters59.  A better method which 
could be used with future development of more assays (3 or more) would be to use latent class 
modeling, modified for sensitivity and specificity calculations59,60.   
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The trend towards positive correlation between viral load and ORF52 ELISA absorbance 
provides evidence of ELISA specificity (Fig. 6). We also recorded that 19/20 qPCR positive cats 
were positive on ELISA. Both of these observations provide assurance that qPCR-/ELISA+ results 
are accurate. As noted, only one cat (G5 from Florida) was qPCR positive and negative on both 
ELISAs. Cat G5 had a relatively high whole-blood viral-DNA load recorded initially and during re-
testing (4491 copies/million cells). This animal was also negative on both ORF65 and ORF17.5 
IFAs. Negative serology and positive qPCR could be explained by a recent infection that had not 
yet resulted in seroconversion. Other explanations include the individual’s inability to produce 
antibodies due to severity of some other immune problems or a sample identification error.   
Most likely the correlative viral load vs ORF52 ELISA absorbance (Fig. 6) also reflects a 
situation where most of the cats that are qPCR positive in this sample set are cats with a re-
activated infection or a late stage primary infection. In both of these situations antibody titer 
and viral load are high61,62. Reactivation would result in higher levels of viral antigen in 
circulation, which would boost anamnestic humoral immune response, causing higher antibody 
loads. ORF38 ELISA absorbance, however, did not show a relationship to FcaGHV1 qPCR viral 
load (Fig.7). There is likely some complex immune activity occurring with this dynamic. Studies 
of KSHV sero-reversion in longitudinal studies of HIV patients have demonstrated plasticity of 
KSHV antibody titers throughout HIV infection and relative to development of KS63. More study 
into the particular activity of the feline FcaGHV1 antibody response is needed to completely 
understand these subtleties. 
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An estimate of how many cats might have an active FcaGHV1 infection in a given year 
gives more information about potential for virus transmission. The samples used in this study 
were collected at each site over a 2 to 3 year period depending on exact site. The estimate 
using qPCR prevalence data is thus 5 to 8 cats out of a 100 cats annually with an active 
infection. This is not a true measure of incidence since a primary infection cannot be detected 
by ELISA or qPCR assay. Based on kinetics of EBV serology patterns, an individual who is in late 
primary infection would have a similar profile as someone with re-activated infection. 
Additionally, viral-DNA load in the blood could also be similar for both infection stages61. It is 
therefore difficult to come to a conclusion about primary versus re-activated infection. 
However, the rate of 5-8 cats out of 100 annually with an active infection does give some idea 
about chances of transmission. Considering a cat fight might be required for transmission, this 
rate of infected animals would also be congruent with interpreting FcaGHV1 seroprevalence 
(35%) as a measure of exposure. Density is another important factor in considering 
transmission rate, and could be further evaluated to assess additional risk factors of FcaGHV1 
exposure. 
The IFA and western blot testing proved to be an effective method of screening 
immunodominant antigens of FcaGHV1 to target certain proteins for high throughput antibody 
screening. The combination of these initial tests allowed me to confirm that at least some 
domestic cats with FcaGHV1 would form antibodies to ORF38 and ORF52.  Western blot proved 
to be a valuable technique in further characterizing immune responses indicated by IFA 
screening assays. The combination of these assays provided me with more confidence against 
false negatives on the ELISAs I developed. In the future, I think they would be good 
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complements to data on new antigen testing, but they could be performed after ELISA 
development as confirmation.  
I encountered background issues on both IFA and western blot.  The alkaline 
phosphatase method of detection had a fairly high level of background that limited western 
blot diagnostic utility and may have contributed to the lack of sensitivity with ORF52. I noted 
that there was a higher level of background on IFA when I was looking at samples exposed to 
cat serum as opposed to the anti-HA antibody. This included SPF naïve cat serum and the 
background was particularly intense around the nucleus of the CRFKs. This was likely a 
generalized reaction of feline serum to the particular feline cell line or to ubiquitous cell culture 
contaminants.  
Most of the proteins, including tegument proteins ORF38 and ORF52 appeared to 
localize to the cytoplasm or a combination of cytoplasm and nucleus of the CRFKs. However 
ORF59 localized only to the nucleus (see Fig. S1). ORF59’s localization to the nucleus during 
transient transfection may be explained by the function of ORF59 gammaherpesvirus 
homologues as the DNA polymerase processivity factor44,64. In KSHV, there is some evidence 
that ORF59 forms a homodimer when it enters the cytoplasm64. If this were the case in 
FcaGHV1 as well, the dimerization may have concealed the HA tag on the recombinant 
construct making it only visible in the nucleus when anti-HA was used as a primary antibody. 
The earlier described higher background with nuclear staining could have also masked ORF59 




There was variation in individual cat antibody response with respect to each antigen of 
FcaGHV1 evaluated in this study. ORF38 and ORF52 proteins both reacted with 65% of all 
seropositive cats, 5% only reacted with ORF38 and 30% only with ORF52. Of the 15 cat sera 
samples that only reacted with one antigen, 20% were also confirmed by qPCR-positive results. 
Variation in humoral immune response is certainly not uncommon but it may be more 
pronounced during gammaherpesvirus infection. Katano et al. evaluated seroprevalence in 
patients with KS for a variety of KSHV antigens. They performed initial testing with a smaller set 
of KS patients using western blot, and noted that seroreactivity to antigens was not uniform. 
Because of the wide range in response, they created a more sensitive ELISA for 5 antigens14. 
The results for cats tested in this assay reflect a similar varied antibody response. Variation may 
be a due to a combination of the complexity of gammaherpesvirus life cycle, variations in host 
immune response, and technicalities of assay development with ORF38 as noted below. 
ORF38 and ORF52 did not have uniform performance across IFA, western blot and ELISA 
(Table 3). The ORF38 ELISA detected 2 individuals positive that were ORF52 ELISA negative 
while ORF52 detected 13 individuals that were ORF38 ELISA negative. There were 28 cats that 
were positive on both ELISAs (Fig. 3). This difference between IFA, western blot, and ELISA 
could be explained by some factor in the conditions of the IFA or the western blot that did not 
allow proper expression of ORF52. An alternative explanation may relate to optimization of the 
ELISA assay. ORF38 had a rather low yield of protein per transfection. I optimized transfection 
efficiency by adjusting amounts of transfection reagents and harvesting at different time points 
for ORF38, however despite this, at best I only arrived at half of the protein production per 
million cells as I did with those exposed to ORF52 transfection. Since we have not yet 
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synthesized and purified large quantities of protein for ELISA optimization, additional assay 
development may enhance the sensitivity of ORF38 as a serologic target. Enhancement of 
antigen production would be a logical next step for standardizing ORF38 and ORF52 ELISAs for 
large-scale reproducible use. 
The antigens identified as immunodominant (ORF38 and ORF52) in this analysis 
represent tegument proteins in other gammaherpesviruses. The tegument is a layer of the virus 
between the envelope and the capsid3. In general herpesvirus proteins have multiple highly 
distinct functions3. Studies of KSHV, Rhesus macaque rhadinovirus, and MHV-68 show that 
ORF38 and ORF52 also potentially provide more efficient virion maturation and egress17,37,38. 
These additional roles may mean high production of these proteins contribute to other aspects 
of their antigenic nature. The proteins that form the tegument are particularly understudied in 
herpes viruses. Studies of Herpes Simplex Virus (HSV) have revealed that HSV particles are 
coated with tegument in the cytoplasm of the host cell 65 66. This corresponds to localization of 
these tegument proteins to the cytoplasm during transient transfection (Fig. 1). HSV tegument 
proteins are known to have roles beyond structure formation including activation of 
glycoproteins and capsid proteins66. There is also evidence that tegument proteins have roles in 
binding to cellular transport proteins67. These additional functions may increase exposure to 
the host immune system. Additionally, variation in pathogen recognition factors likely plays an 
important role.  
KSHV data suggests that sensitivity of mixed-antigen ELISAs can increase with use of a 
combination of latent and lytic protein antigens14. In this study we did not evaluate proteins 
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that are considered to be homologous to herpesvirus proteins expressed during latency. There 
is potential to pursue this in the future with the FcaGHV1 homologue to KSHV’s LANA. That 
said, the ELISAs developed in this study are likely a fairly accurate measure of exposure, it could 
be a small percentage that are being missed by not evaluating further antigens.  
A case-control study of cats that have been co-infected with FIV and FcaGHV1 would 
allow for in-depth observations of many aspects of FcaGHV1 and would be the ideal setting to 
evaluate a full panel of screening ELISAs tested sequentially during FcaGHV1 infection. Co-
infected cats would be compared to uninfected cats as well as cats with a singular infection. A 
study of this type has the potential to quickly answer questions discussed earlier about 
FcaGHV1 transmission, pathogenesis, and viral kinetics. It could provide information about 
actual clinical disease associations with FcaGHV1 and the value of therapeutic interventions. 
This could potentially advance understanding of the FcaGHV1 life cycle as well.  
Studying EBV and KSHV has been difficult because they are complex viruses with large 
DNA genomes. Furthermore, the associated lifelong latency periods make study of transmission 
and reactivation even more difficult and have been a challenge for effective vaccine 
development. Appropriate animal models allow us to better study these sorts of details rather 
than relying on human longitudinal studies that attempt to make up for an inability to 
manipulate study variables. Consequently, one of the most important benefits of feline case-
control studies of FcaGHV1 would be to evaluate the potential for a feline model of HIV/GHV 








Indirect ELISA based upon FcaGHV1 tegument associated antigens ORF52 and ORF38 
ELISA provided an enhanced assay to detect viral exposure compared to FcaGHV1 qPCR. We 
concluded that approximately half of seropositive cats have a detectable FcaGHV1 viral 
genomes using qPCR.  
This study additionally showed strong support of risk factors of FcaGHV1 infection 
identified previously. Adult male cats are much more likely to be both seropositive and have 
peripheral-blood viral load. There was also a relationship between co-infection with other 
pathogens and detection of FcaGHV1 seropositivity. These factors point strongly toward inter-
cat aggression as a mode of transmission.  
It may appear from this data set that ORF52 ELISA alone would provide accurate and 
sensitive seroprevalence information. However, given what we know about individual and 
regional variations in sero-response of KSHV, I believe the ORF38 ELISA is an important addition 
to the ELISA. Ideally, antigens could be optimized for use in a multiplex assay. Additions of other 
antigens to the ELISA could also be explored, preferably in settings of more controlled 
experimentation such as case-control studies. 
IFA and western blot assays proved to be useful tools for bolstering assurance of 
specificity during ELISA development. In the future they will be helpful techniques that could 
also be used after ELISA development instead of before. To improve the ELISA assay a more 
productive method of producing ORF38 and ORF52 will also be important.  
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Other results of this study suggest the biology of FcaGHV1 is more similar to KSHV than 
EBV infection in humans, illustrating potential utility of studying FcaGHV1 infection to aid 
studies of KSHV disease. It would be important to design studies aimed at identifying disease 
associations and routes of transmission to confirm observations made in this initial study. 
Ideally, future studies would evaluate FcaGHV1 incidence in populations of cats by both qPCR 
and ELISA. I would target disease patterns such as chronic lymphocytic leukemia, inflammatory 
bowel disease, B cell lymphocytosis, and intestinal lymphoma and assess both FcaGHV1 
seropositivity and qPCR. Based on our knowledge of gammaherpesviruses and common clinical 
syndromes in cats that have lymphoproliferative tendencies, these would be the most likely 
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